Compare Stocks

Comparative Price Performance Over Time

Compare Stocks - Price & Volume

CompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's Volume
Gemphire Therapeutics Inc stock logo
GEMP
Gemphire Therapeutics
$3.12
-7.4%
$4.97
$0.24
$1.49
$46.40M2.82127,174 shs23,389 shs
Biodexa Pharmaceuticals Plc stock logo
MTP
Biodexa Pharmaceuticals
$1.95
$0.29
$5.25
$6.18M2.2957,354 shs164,300 shs
NSPX
Inspyr Therapeutics
$0.00
$0.00
$0.07
$1.47M-17.3313.19 million shs29.64 million shs
Sienna Biopharmaceuticals, Inc. stock logo
SNNA
Sienna Biopharmaceuticals
$0.14
$0.14
$0.06
$3.80
$4.20M2.671.87 million shs13.32 million shs
Xenetic Biosciences Inc stock logo
XBIO
Xenetic Biosciences
$3.85
+2.4%
$4.08
$2.55
$5.97
$5.79M2.67,203 shs2,719 shs
7 Energy Stocks to Buy and Hold Forever Cover

Do you expect the global demand for energy to shrink?! If not, it's time to take a look at how energy stocks can play a part in your portfolio.

Get This Free Report

Price Performance

Company1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year Performance
Gemphire Therapeutics Inc stock logo
GEMP
Gemphire Therapeutics
-7.42%-11.61%-30.04%-1.89%+358.15%
Biodexa Pharmaceuticals Plc stock logo
MTP
Biodexa Pharmaceuticals
0.00%0.00%0.00%0.00%0.00%
NSPX
Inspyr Therapeutics
0.00%0.00%0.00%0.00%0.00%
Sienna Biopharmaceuticals, Inc. stock logo
SNNA
Sienna Biopharmaceuticals
0.00%0.00%0.00%0.00%0.00%
Xenetic Biosciences Inc stock logo
XBIO
Xenetic Biosciences
+1.85%-4.11%-0.26%+17.74%-12.02%

MarketRank™

CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & Valuation
Gemphire Therapeutics Inc stock logo
GEMP
Gemphire Therapeutics
N/AN/AN/AN/AN/AN/AN/AN/A
Biodexa Pharmaceuticals Plc stock logo
MTP
Biodexa Pharmaceuticals
N/AN/AN/AN/AN/AN/AN/AN/A
NSPX
Inspyr Therapeutics
N/AN/AN/AN/AN/AN/AN/AN/A
Sienna Biopharmaceuticals, Inc. stock logo
SNNA
Sienna Biopharmaceuticals
N/AN/AN/AN/AN/AN/AN/AN/A
Xenetic Biosciences Inc stock logo
XBIO
Xenetic Biosciences
N/AN/AN/AN/AN/AN/AN/AN/A

Analyst Ratings

CompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current Price
Gemphire Therapeutics Inc stock logo
GEMP
Gemphire Therapeutics
N/AN/AN/AN/A
Biodexa Pharmaceuticals Plc stock logo
MTP
Biodexa Pharmaceuticals
N/AN/AN/AN/A
NSPX
Inspyr Therapeutics
N/AN/AN/AN/A
Sienna Biopharmaceuticals, Inc. stock logo
SNNA
Sienna Biopharmaceuticals
N/AN/AN/AN/A
Xenetic Biosciences Inc stock logo
XBIO
Xenetic Biosciences
2.00
HoldN/AN/A

Current Analyst Ratings

Sales & Book Value

CompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/Book
Gemphire Therapeutics Inc stock logo
GEMP
Gemphire Therapeutics
N/AN/AN/AN/A$0.54 per shareN/A
Biodexa Pharmaceuticals Plc stock logo
MTP
Biodexa Pharmaceuticals
$800K0.00N/AN/A$5.67 per share0.00
NSPX
Inspyr Therapeutics
N/AN/AN/AN/A($0.07) per shareN/A
Sienna Biopharmaceuticals, Inc. stock logo
SNNA
Sienna Biopharmaceuticals
N/AN/AN/AN/A$1.27 per shareN/A
Xenetic Biosciences Inc stock logo
XBIO
Xenetic Biosciences
$2.54M2.33N/AN/A$6.36 per share0.61

Profitability & Earnings

CompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings Date
Gemphire Therapeutics Inc stock logo
GEMP
Gemphire Therapeutics
-$23.64MN/A0.00N/AN/A-419.70%-173.05%N/A
Biodexa Pharmaceuticals Plc stock logo
MTP
Biodexa Pharmaceuticals
-$7.51MN/A0.00N/AN/AN/AN/AN/AN/A
NSPX
Inspyr Therapeutics
-$6.30MN/A0.00N/AN/AN/AN/A-1,354.49%N/A
Sienna Biopharmaceuticals, Inc. stock logo
SNNA
Sienna Biopharmaceuticals
-$73.47M-$3.59N/AN/AN/AN/A-177.36%-52.22%N/A
Xenetic Biosciences Inc stock logo
XBIO
Xenetic Biosciences
-$4.14M-$2.75N/AN/AN/A-162.84%-36.43%-33.74%5/9/2024 (Estimated)

Latest XBIO, NSPX, SNNA, MTP, and GEMP Earnings

DateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails
3/21/2024Q4 2023
Xenetic Biosciences Inc stock logo
XBIO
Xenetic Biosciences
-$0.87-$0.77+$0.10-$0.77$0.68 million$0.67 million

Dividends

CompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive Growth
Gemphire Therapeutics Inc stock logo
GEMP
Gemphire Therapeutics
N/AN/AN/AN/AN/A
Biodexa Pharmaceuticals Plc stock logo
MTP
Biodexa Pharmaceuticals
N/AN/AN/AN/AN/A
NSPX
Inspyr Therapeutics
N/AN/AN/AN/AN/A
Sienna Biopharmaceuticals, Inc. stock logo
SNNA
Sienna Biopharmaceuticals
N/AN/AN/AN/AN/A
Xenetic Biosciences Inc stock logo
XBIO
Xenetic Biosciences
N/AN/AN/AN/AN/A

Debt

CompanyDebt-to-Equity RatioCurrent RatioQuick Ratio
Gemphire Therapeutics Inc stock logo
GEMP
Gemphire Therapeutics
N/A
0.67
0.67
Biodexa Pharmaceuticals Plc stock logo
MTP
Biodexa Pharmaceuticals
N/AN/AN/A
NSPX
Inspyr Therapeutics
N/A
0.09
0.09
Sienna Biopharmaceuticals, Inc. stock logo
SNNA
Sienna Biopharmaceuticals
N/A
15.27
15.27
Xenetic Biosciences Inc stock logo
XBIO
Xenetic Biosciences
N/A
11.84
11.84

Ownership

Miscellaneous

CompanyEmployeesShares OutstandingFree FloatOptionable
Gemphire Therapeutics Inc stock logo
GEMP
Gemphire Therapeutics
914.87 millionN/ANot Optionable
Biodexa Pharmaceuticals Plc stock logo
MTP
Biodexa Pharmaceuticals
1821.67 million21.60 millionNot Optionable
NSPX
Inspyr Therapeutics
1543.15 millionN/ANot Optionable
Sienna Biopharmaceuticals, Inc. stock logo
SNNA
Sienna Biopharmaceuticals
3930.91 millionN/ANot Optionable
Xenetic Biosciences Inc stock logo
XBIO
Xenetic Biosciences
41.54 million1.40 millionNot Optionable

XBIO, NSPX, SNNA, MTP, and GEMP Headlines

SourceHeadline
Xenetic Biosciences Inc (XBIO)Xenetic Biosciences Inc (XBIO)
investing.com - April 10 at 3:28 PM
Xenetic Biosciences Full Year 2023 Earnings: EPS Beats Expectations, Revenues LagXenetic Biosciences Full Year 2023 Earnings: EPS Beats Expectations, Revenues Lag
finance.yahoo.com - March 24 at 5:09 PM
Xenetic Dips on Full-Year ResultsXenetic Dips on Full-Year Results
baystreet.ca - March 22 at 7:33 PM
Xenetic Biosciences reports FY resultsXenetic Biosciences reports FY results
msn.com - March 22 at 8:51 AM
Xenetic Biosciences, Inc. Reports Full Year 2023 Financial ResultsXenetic Biosciences, Inc. Reports Full Year 2023 Financial Results
accesswire.com - March 22 at 8:00 AM
Xenetic to advance DNase programme with UVA partnershipXenetic to advance DNase programme with UVA partnership
msn.com - January 18 at 1:37 PM
Xenetic Biosciences Inc XBIOXenetic Biosciences Inc XBIO
morningstar.com - January 4 at 5:10 PM
Xenetic Biosciences Stock (NASDAQ:XBIO), Guidance and ForecastXenetic Biosciences Stock (NASDAQ:XBIO), Guidance and Forecast
benzinga.com - December 11 at 9:01 AM
Most Shareholders Will Probably Agree With Xenetic Biosciences, Inc.s (NASDAQ:XBIO) CEO CompensationMost Shareholders Will Probably Agree With Xenetic Biosciences, Inc.'s (NASDAQ:XBIO) CEO Compensation
finance.yahoo.com - November 30 at 10:39 AM
Xenetic Biosciences: Q3 Earnings InsightsXenetic Biosciences: Q3 Earnings Insights
benzinga.com - November 10 at 3:38 PM
MediciNova: Q3 Earnings SnapshotMediciNova: Q3 Earnings Snapshot
washingtonpost.com - November 10 at 10:37 AM
Xenetic Biosciences, Inc. to Participate at the Virtual Investor Ask the CEO ConferenceXenetic Biosciences, Inc. to Participate at the Virtual Investor Ask the CEO Conference
finance.yahoo.com - October 11 at 9:30 AM
Xenetic Biosciences (XBIO) Upgraded to Strong Buy: What Does It Mean for the Stock?Xenetic Biosciences (XBIO) Upgraded to Strong Buy: What Does It Mean for the Stock?
msn.com - July 13 at 1:44 PM
Xenetic Biosciences, Inc. Reports First Quarter 2023 Financial Results and Provides Business UpdateXenetic Biosciences, Inc. Reports First Quarter 2023 Financial Results and Provides Business Update
finance.yahoo.com - May 11 at 5:06 PM
Xenetic Biosciences, Inc. Adds Business Development Expertise with Appointment of Scott N. Cullison | MorningstarXenetic Biosciences, Inc. Adds Business Development Expertise with Appointment of Scott N. Cullison | Morningstar
morningstar.com - May 5 at 10:21 AM
Xenetic Biosciences, Inc. Bolsters R&D and Regulatory Expertise with Appointment of Reid P. Bissonnette, Ph.D. as Executive Consultant for Translational Research and DevelopmentXenetic Biosciences, Inc. Bolsters R&D and Regulatory Expertise with Appointment of Reid P. Bissonnette, Ph.D. as Executive Consultant for Translational Research and Development
finance.yahoo.com - May 4 at 10:02 AM
Xenetic Biosciences, Inc. Adds Business Development Expertise with Appointment of Scott N. CullisonXenetic Biosciences, Inc. Adds Business Development Expertise with Appointment of Scott N. Cullison
finance.yahoo.com - May 3 at 10:26 AM
HC Wainwright & Co. Reiterates Xenetic Biosciences (XBIO) Buy RecommendationHC Wainwright & Co. Reiterates Xenetic Biosciences (XBIO) Buy Recommendation
msn.com - April 12 at 10:37 PM
Xenetic Biosciences forms research collaboration with TSRIXenetic Biosciences forms research collaboration with TSRI
pharmaceutical-technology.com - April 12 at 12:36 PM
Analysts Offer Insights on Healthcare Companies: Adaptimmune Therapeutics (ADAP) and Xenetic Biosciences (XBIO)Analysts Offer Insights on Healthcare Companies: Adaptimmune Therapeutics (ADAP) and Xenetic Biosciences (XBIO)
markets.businessinsider.com - April 12 at 2:30 AM
Xenetic Biosciences, Inc. Announces Research and Development Collaboration with The Scripps Research Institute to Advance DNase PlatformXenetic Biosciences, Inc. Announces Research and Development Collaboration with The Scripps Research Institute to Advance DNase Platform
finance.yahoo.com - April 11 at 8:43 AM
JTC Team, LLC: JTC Team to Host Virtual Investor NETs in Cancer Spotlight Event Featuring Xenetic BiosciencesJTC Team, LLC: JTC Team to Host Virtual Investor NETs in Cancer Spotlight Event Featuring Xenetic Biosciences
finanznachrichten.de - March 16 at 12:09 PM
JTC Team to Host Virtual Investor NETs in Cancer Spotlight Event Featuring Xenetic BiosciencesJTC Team to Host Virtual Investor NETs in Cancer Spotlight Event Featuring Xenetic Biosciences
finance.yahoo.com - March 16 at 12:09 PM
XBIO Xenetic Biosciences, Inc.XBIO Xenetic Biosciences, Inc.
seekingalpha.com - February 23 at 11:29 PM

New MarketBeat Followers Over Time

Media Sentiment Over Time

Company Descriptions

Gemphire Therapeutics logo

Gemphire Therapeutics

NASDAQ:GEMP
Gemphire Therapeutics Inc., a clinical-stage biopharmaceutical company, focuses on developing and commercializing therapies for the treatment of dyslipidemia and nonalcoholic fatty liver disease (NAFLD/NASH). The company is developing gemcabene, a novel, once-daily, and oral therapy for dyslipidemia conditions where patients are unable to reach their lipid lowering goals, including patients already receiving maximally tolerated statin therapy. It also completed three Phase IIb clinical trials for gemcabene in homozygous familial hypercholesterolemia (HoFH) and hypercholesterolemia, including heterozygous familial hypercholesterolemic (HeFH) and atherosclerotic cardiovascular disease (ASCVD) patients on maximally tolerated statins, and severe hypertriglyceridemia (SHTG). The company was founded in 2008 and is headquartered in Livonia, Michigan.
Biodexa Pharmaceuticals logo

Biodexa Pharmaceuticals

NASDAQ:MTP
Biodexa Pharmaceuticals Plc is a drug delivery technology company. It is focused on the research and development of medicines for rare cancers, via both in-house programs as well as partnered programs. The firm's proprietary platform drug delivery technologies are Q-Sphera platform is a disruptive polymer microsphere technology, which is used for sustained release at the microscale to prolong and control the release of therapeutics over an extended period of time from weeks to months; Midasolve platform is an innovative nano saccharide technology, which is used to dissolve drugs at the nanoscale so that they can be administered in liquid form directly and locally into tumors; Midacore platform is an edge gold nanoparticle technology, which is used for targeting sites of disease at the nanoscale. The company was founded in 2000 and is headquartered in Cardiff, the United Kingdom.

Inspyr Therapeutics

OTCMKTS:NSPX
Inspyr Therapeutics, Inc. is a pharmaceutical company, which engages in the research and development of novel therapeutics for the treatment of cancer. Its product pipeline includes Mipsagargin, a dual A2A/A2B antagonist, an A2A antagonist, an A2B antagonist, and an A2A agonist. The company was founded by Craig A. Dionne, John T. Issacs, and Samuel R. Denmeade on November 21, 2003 and is headquartered in Westlake Village, CA.
Sienna Biopharmaceuticals logo

Sienna Biopharmaceuticals

NASDAQ:SNNA
Sienna Biopharmaceuticals, Inc. is a clinical-stage biopharmaceutical company that focuses on the discovery, clinical development, and commercialization of aesthetics and medical dermatology. Its products include Topical by Design platform for patients with inflammatory skin diseases and other dermatologic and aesthetic conditions through SNA-120, SNA-125, and SNA-001. The company was founded by Todd Harris and Frederick C. Beddingfield III on July 27, 2010 and is headquartered in Westlake Village, CA.
Xenetic Biosciences logo

Xenetic Biosciences

NASDAQ:XBIO
Xenetic Biosciences, Inc. is a biopharmaceutical company focused on progressing XCART, a personalized CAR T platform technology engineered to target patient-specific tumor neoantigens. The Company is initially advancing cell-based therapeutics targeting the unique B-cell receptor on the surface of an individual patient's malignant tumor cells for the treatment of B-cell lymphomas. XCART has the potential to fuel a robust pipeline of therapeutic assets targeting high-value oncology indications.